SCHEMBL5515965

SCHEMBL5515965

O=C(NCc1ccccc1)c1nccc(O)c1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.61
ALDH1A1 P00352 1/20 0.54
GAA P10253 1/20 0.54
EGLN1 Q9GZT9 3/20 0.52
EGFR P00533 2/20 0.52
LCK P06239 1/20 0.52
MMP13 P45452 1/20 0.51
RAB9A P51151 1/20 0.50
LMNA P02545 2/20 0.49
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HPGDS O60760 2/20 0.49
NSD2 O96028 1/20 0.48
ROCK2 O75116 1/20 0.48
RPS6KA5 O75582 1/20 0.48
MAP4K4 O95819 1/20 0.48
PRKCG P05129 1/20 0.48
PRKACA P17612 1/20 0.48
RPS6KB1 P23443 1/20 0.48
MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29480457 0.90 KMT2A (0.51) KMT2AALDH1A1GAAEGLN1EGFR
Hydrochloric Acid SCHEMBL29480330 0.89 KMT2A (0.50) KMT2AALDH1A1GAAEGLN1EGFR
SCHEMBL6372451 0.85 KMT2A (0.56) KMT2AALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL29480266 0.83 MMP8 (0.48) KMT2AALDH1A1EGFRLCKSMN1; SMN2
SCHEMBL31026221 0.83 EGLN2 (0.68) KMT2AALDH1A1GAAEGLN1EGFR
SCHEMBL29480399 0.82 ALDH1A1 (0.54) KMT2AALDH1A1
Hydrochloric Acid SCHEMBL29480182 0.82 MMP8 (0.47) KMT2AALDH1A1EGFRLCKSMN1; SMN2
SCHEMBL5583853 0.82 KMT2A (0.58) KMT2AALDH1A1GAALMNAHTT
Hydrochloric Acid SCHEMBL29480299 0.81 ALDH1A1 (0.53) KMT2AALDH1A1
SCHEMBL8790412 0.79 RAB9A (0.77) KMT2AALDH1A1GAAEGLN1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760834-B1 PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL MYERS SQUIBB CO (US) 2016-11-16 EP disclosed
CN-101014571-A N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as HIV integrase inhibitors MERCK & CO INC (US) 2007-08-08 CN disclosed
CN-101014571-A N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as HIV integrase inhibitors MERCK & CO INC (US) 2007-08-08 CN disclosed
CN-101014571-A N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as HIV integrase inhibitors MERCK & CO INC (US) 2007-08-08 CN disclosed
US-20070155744-A1 N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P, ANGELETTI S.P.A. (IT) 2007-07-05 US disclosed
US-20070155744-A1 N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P, ANGELETTI S.P.A. (IT) 2007-07-05 US disclosed
US-20070155744-A1 N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P, ANGELETTI S.P.A. (IT) 2007-07-05 US disclosed
EP-1713773-A2 N-BENZYL-3,4-DIHYROXYPYRIDINE-2-CARBOXAMIDE AND N-BENZYL-2,3-DIHYDROXYPYRIDINE-4-CARBOXAMIDE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-10-25 EP disclosed
EP-1713773-A2 N-BENZYL-3,4-DIHYROXYPYRIDINE-2-CARBOXAMIDE AND N-BENZYL-2,3-DIHYDROXYPYRIDINE-4-CARBOXAMIDE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-10-25 EP disclosed
WO-2005074513-A3 N-BENZYL-3,4-DIHYROXYPYRIDINE-2-CARBOXAMIDE AND N-BENZYL-2,3-DIHYDROXYPYRIDINE-4-CARBOXAMIDE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2005-09-29 WO disclosed
WO-2005074513-A2 N-BENZYL-3,4-DIHYROXYPYRIDINE-2-CARBOXAMIDE AND N-BENZYL-2,3-DIHYDROXYPYRIDINE-4-CARBOXAMIDE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-08-18 WO disclosed
WO-2005074513-A2 N-BENZYL-3,4-DIHYROXYPYRIDINE-2-CARBOXAMIDE AND N-BENZYL-2,3-DIHYDROXYPYRIDINE-4-CARBOXAMIDE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155744-A1 N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors DUT, NQO2, TYMP KMT2A 469/4885ALDH1A1 2368/4885GAA 1422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.